WA
MYGN icon

Wasatch Advisors’s Myriad Genetics MYGN Stock Holding History

Wasatch Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,600
Closed -$239K – 312
2017
Q3 		$239K Buy
+6,600
New +$188K ﹤0.01% 315
2017
Q2 		– Sell
-12,100
Closed -$232K – 351
2017
Q1 		$232K Hold
12,100
– – ﹤0.01% 338
2016
Q4 		$202K Hold
12,100
– – ﹤0.01% 356
2016
Q3 		$249K Sell
12,100
-9,000
-43% -$228K ﹤0.01% 347
2016
Q2 		$646K Sell
21,100
-1,200
-5% -$41.7K 0.01% 333
2016
Q1 		$831K Buy
+22,300
New +$840K 0.01% 333
2014
Q1 		– Sell
-132,960
Closed -$2.79M – 396
2013
Q4 		$2.79M Sell
132,960
-806,766
-86% -$20.4M 0.03% 293
2013
Q3 		$22.1M Buy
939,726
+42,357
+5% +$1.2M 0.23% 134
2013
Q2 		$24.1M Buy
+897,369
New +$26M 0.26% 123

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wasatch Advisors's MYGN Position: Q4 2017 in Review

Wasatch Advisors sold out of Myriad Genetics (MYGN) in Q4 2017, closing a stake of 6,600 shares — an estimated $239K sold.

Wasatch Advisors first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $24.1M in Q2 2013. 250 funds tracked by Wall St. Rank hold MYGN as of Q4 2017.

  • Wasatch Advisors reported no remaining Myriad Genetics position as of Q4 2017 after selling out during the quarter.
  • Wasatch Advisors sold 6,600 Myriad Genetics shares in Q4 2017, an estimated $239K.
  • Wasatch Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
  • Wasatch Advisors's Myriad Genetics position peaked at $24.1M in Q2 2013.
  • 250 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2017.

Based on Wasatch Advisors's 13F filing for Q4 2017, filed 16 Jan 2018.